As per the research report, the size of the Europe Biopharmaceutical Contract Manufacturing market is valued at USD 1.64 billion in 2021. It is expected to rise at a CAGR of 9.3% capping the market to USD 2.56 billion by 2026.
Biopharmaceuticals is a biological product manufactured and developed to address the prevention and treatment of various diseases. Recent advancements in biomanufacturing and biotechnology have triggered the growth of innovative technologies that are capable of addressing the difficulties related to the manufacture of Biopharmaceuticals. Consequently, there is a rise in Biopharmaceutical contract manufacturing market growth. Previously, the Biopharmaceutical market was aimed towards preventive Biopharmaceuticals and mass production against infectious diseases. The commencement of therapeutic Biopharmaceuticals has altered interest in the field by creating a method for Biopharmaceuticals to be industrialized for a variety of chronic and progressive ailments, which has endorsed the entry of a number of manufacturers and budding investors who are contending for a market investment in this potential market segment.
This research report segmented and sub-segmented into the following categories:
Europe's Biopharmaceutical industry is controlled by strict Drug Authority regulations and tough patent rights. The region has state of the art technology to manufacture the drugs with utmost efficiency. The market is also largely influenced by the recommended new drugs that come into the market after receiving product clearance.
Key players operating in the Europe Biopharmaceutical contract manufacturing market profiled in this report are Lonza Group AG, Baxter Biopharma Solutions, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, Probiogen AG, Cytovance Biologics, Inc., KBI Biopharma, Inc., WuXi Biologics, Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent, Inc., AbbVie Contract Manufacturing (An AbbVie Company), Ajinomoto Althea Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Insulin
5.1.3 Monoclonal Antibodies
5.1.4 Growth Factors
5.1.5 Interferons
5.1.6 Recombinant Protiens
5.1.7 Vaccines
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Product Type
5.1.10 Market Attractiveness Analysis, By Product Type
5.1.11 Market Share Analysis, By Product Type
5.2 Therapeutic Area
5.2.1 Introduction
5.2.2 Infectious Disease
5.2.3Cardiovascular Disease
5.2.4 Oncology
5.2.5 Metabolic Disease
5.2.6 Respiratory Disorder
5.2.7 Autoimmune Disease
5.2.8 Neurology
5.2.9 Ophthalmology
5.2.10 Others
5.2.11 Y-o-Y Growth Analysis, By Therapeutic Area
5.2.12 Market Attractiveness Analysis, By Therapeutic Area
5.2.13 Market Share Analysis, By Therapeutic Area
5.3 Application
5.3.1 Introduction
5.3.2 Clinical
5.3.3 Commercial
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By Therapeutic Area
6.1.3.4 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By Therapeutic Area
6.1.4.4 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By Therapeutic Area
6.1.5.4 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Patheon N.V.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2Rentschler Biotechnologie GmbH
8.3 AbbVie Contract Manufacturing (An AbbVie Company)
8.4 Biomeva GmbH
8.5 Boehringer Ingelheim GmbH
8.6 WuXi Biologics
8.7 Abzena Plc
8.8 Lonza Group AG
8.9 Samsung Biologics Co.
8.10 Ajinomoto Althea, Inc.
8.11 Fujifilm Diosynth Biotechnologies
8.12 Probiogen AG
8.13 Sandoz International GmbH
8.14 KBI Biopharma, Inc.
8.15 Baxter Biopharma Solutions
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
